We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
41.00 | 2.26% | 1,854.00 | 1,839.00 | 1,841.00 | 1,882.00 | 1,750.00 | 1,750.00 | 760,985 | 16:35:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 21.19 | 4.07B |
TIDMHIK
RNS Number : 9963O
Hikma Pharmaceuticals Plc
25 August 2017
TR-1: Standard form for notification of major holdings
LONDON, 25 August 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75), the fast-growing multinational pharmaceuticals group, announces as follows:
NOTIFICATION OF MAJOR HOLDINGS
1. Identity of the issuer or Hikma Pharmaceuticals PLC the underlying issuer of existing shares to which voting rights are attached: (ii) ---------------------------------------------------------- --------------------------- 2. Reason for the notification (please tick the appropriate box or boxes): --------------------------------------------------------------------------------------- An acquisition or disposal of voting rights YES ----------------------------------------------------------- -------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ----------------------------------------------------------- -------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ----------------------------------------------------------- -------------------------- An event changing the breakdown of voting rights ----------------------------------------------------------- -------------------------- Other (please specify): --------------------------------------------------------- -------------------------- 3. Full name of person(s) Vanguard Health Care Fund subject to the notification obligation: (iii) ---------------------------------------------------------- --------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ---------------------------------------------------------- --------------------------- 5. Date of the transaction 22 August 2017 and date on which the threshold is crossed or reached: (v) ---------------------------------------------------------- --------------------------- 6. Date on which issuer 24 August 2017 notified: ---------------------------------------------------------- --------------------------- 7. Threshold(s) that is/are crossed or reached: (vi, vii) 3% ---------------------------------------------------------- --------------------------- 8. Notified details: -------------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) -------------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ---------------- -------------------------------- ---------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights -------------- --------------- --------------- ----------------- -------------------------- ----------------------- Direct Direct (xi) Indirect Direct Indirect (xii) -------------- ----------- ----------- ----------------- ------------- ----------- ---------- ----------- GB00B0LCW083 7,186,729 7,186,729 7,284,981 7,284,981 3.03% --------------- --------------- ----------------- ------------- ----------- ---------- ----------- B: Qualifying Financial Instruments -------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction -------------------------------------------------------------------------------------------------------------------------- Type of financial Expiration Exercise/ Number of voting % of voting instrument date Conversion rights that rights (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ------------------ --------------- ------------------------------ ------------------------------ --------------------- N/A ------------------ --------------- ------------------------------ ------------------------------ --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) -------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction -------------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) -------------- --------------- --------------- --------------- ------------------------------ ----------------------- N/A Nominal Delta -------------- --------------- --------------- --------------- ------------------------------ ------------ --------- Total (A+B+C) -------------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ----------------------------------------------------------------- ------------------------------------------------------- 7,284,981 3.03% ----------------------------------------------------------------- ------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) -------------------------------------------------------------------------------------------------------------------------- N/A Proxy Voting: -------------------------------------------------------------------------------------------------------------------------- 10. Name of the proxy holder: N/A ----------------------------------------------------------------------- ------------------------------------------------- 11. Number of voting rights proxy holder will cease to hold: ----------------------------------------------------------------------- ------------------------------------------------- 12. Date on which proxy holder will cease to hold voting rights: ----------------------------------------------------------------------- ------------------------------------------------- 13. Additional information: ---------------------------------------------------- -------------------------------------------------------------------- 14. Contact name: Vanguard Health Care Fund c/o The Vanguard Group, Inc. Vanguard_Fund_Compliance@Vanguard.com ---------------------------------------------------- -------------------------------------------------------------------- 15. Contact telephone number: +001 (610) 669-8989 ---------------------------------------------------- --------------------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUVOBRBVAWURR
(END) Dow Jones Newswires
August 25, 2017 03:41 ET (07:41 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions